The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Open accessAbstract
INTRODUCTION: Research over the past three decades has identified p53 as a multi-functional transcription factor. p53 influences myriad, highly diverse cellular processes, and represents one of the most important and extensively studied tumor suppressors. Activated by various stresses, p53 blocks cancer progression by provoking transient or permanent growth arrest, by enabling DNA repair, or by advancing cellular death programs. This anti-cancer activity profile, together with genomic and mutational analyses documenting inactivation of p53 in more than 50% of human cancers, motivated drug development efforts to (re-) activate p53 in established tumors. AREAS COVERED: The complexities of p53 signaling in cancer are summarized, including current strategies and challenges to restore p53's tumor suppressive function in established tumors, to inactivate p53 inhibitors, and to restore wild type function of p53 mutant proteins. EXPERT OPINION: p53 represents an attractive target for the development of anti-cancer therapies. Whether p53 is 'druggable', however, remains an area of active research and discussion, as p53 has pro-survival functions and chronic p53 activation accelerates aging, which may compromise the long-term homeostasis of an organism. The complex biology and dual functions of p53 in cancer prevention and age-related cellular responses pose significant challenges to the development of p53-targeting cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Hematopoiesis: An Evolving Paradigm for Stem Cell Biology
Orkin, S. H., & Zon, L. I. (2008) · Cell · doi:10.1016/j.cell.2008.01.025 · Cited by 2,570
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“What are the molecular parameters that determine the cellular fate of transient cell cycle arrest versus senescence? It may depend on additional signals that cooperate with p53, such as Rb-induced senescence-associated heterochromatin foci to silence E2F target genes, as coactivation of Rb--E2F and p53 axes permanentl…”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Identified in the 1970s as a binding partner for the SV40 tumor virus oncoprotein large T antigen and an important target for tumorigenic processes induced by DNA tumor viruses [2-5], research in the late 1980s and 1990s validated p53 as a tumor suppressor gene, as p53 mutations were found in up to 50% of human cancer…”
Background
Research works printed but not linked: 137
- Vousden KH, 2007, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
- Lane DP, 1979, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
- 10.1016/0092-8674(82)90356-7 · DOI · Paper page
- Werness BA, 1990, Science, 248, 76, 10.1126/science.2157286 · DOI · Paper page
- Scheffner M, 1990, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 · DOI · Paper page
- 10.1101/cshperspect.a001016 · DOI · Paper page
- Yonish-Rouach E, 1991, Nature, 352, 345, 10.1038/352345a0 · DOI · Paper page
- Clarke AR, 1993, Nature, 362, 849, 10.1038/362849a0 · DOI · Paper page
- Lowe SW, 1993, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
- Sheikh MS, 1998, Cancer Res, 58, 1593
- Peter ME, 2003, Cell Death Differ, 10, 26, 10.1038/sj.cdd.4401186 · DOI · Paper page
- Ehrhardt H, 2008, Oncogene, 27, 783, 10.1038/sj.onc.1210666 · DOI
- Attardi LD, 2000, Genes Dev, 14, 704, 10.1101/gad.14.6.704 · DOI · Paper page
- Davies L, 2009, J Cell Mol Med, 13, 1995, 10.1111/j.1582-4934.2008.00590.x · DOI
- Stegh AH, 2001, Cardiol Clin, 19, 13, 10.1016/S0733-8651(05)70192-2 · DOI
- Youle RJ, 2008, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 · DOI · Paper page
- Miyashita T, 1995, Cell, 80, 293, 10.1016/0092-8674(95)90513-8 · DOI · Paper page
- Yu J, 2001, Mol Cell, 7, 673, 10.1016/S1097-2765(01)00213-1 · DOI · Paper page
- Nakano K, 2001, Mol Cell, 7, 683, 10.1016/S1097-2765(01)00214-3 · DOI · Paper page
- Han J, 2001, Proc Natl Acad Sci USA, 98, 11318, 10.1073/pnas.201208798 · DOI · Paper page
- 10.1126/science.284.5411.156 · DOI · Paper page
- Jeffers JR, 2003, Cancer Cell, 4, 321, 10.1016/S1535-6108(03)00244-7 · DOI · Paper page
- Chipuk JE, 2003, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
- Caelles C, 1994, Nature, 370, 220, 10.1038/370220a0 · DOI · Paper page
- Johnson TM, 2008, Proc Natl Acad Sci USA, 105, 1215, 10.1073/pnas.0706764105 · DOI
- Chipuk JE, 2005, Science, 309, 1732, 10.1126/science.1114297 · DOI · Paper page
- Mihara M, 2003, Mol Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
- Leu JI, 2004, Nat Cell Biol, 6, 443, 10.1038/ncb1123 · DOI · Paper page
- 10.4161/cc.7.18.6759 · DOI
- Stegh AH, 2008, Proc Natl Acad Sci USA, 105, 10703, 10.1073/pnas.0712034105 · DOI
- Stegh AH, 2007, Genes Dev, 21, 98, 10.1101/gad.1480007 · DOI
- Stegh AH, 2010, Genes Dev, 24, 2194, 10.1101/gad.1924710 · DOI
- 10.4161/cc.10.1.14365 · DOI
- Kumar S, 2009, Nat Rev Cancer, 9, 897, 10.1038/nrc2745 · DOI
- Tinel A, 2004, Science, 304, 843, 10.1126/science.1095432 · DOI · Paper page
- Lin Y, 2000, Nat Genet, 26, 122, 10.1038/79102 · DOI · Paper page
- Zong WX, 2006, Genes Dev, 20, 1, 10.1101/gad.1376506 · DOI · Paper page
- Yuan J, 2010, Genes Dev, 24, 2592, 10.1101/gad.1984410 · DOI · Paper page
- Tu HC, 2009, Proc Natl Acad Sci USA, 106, 1093, 10.1073/pnas.0808173106 · DOI
- Giono LE, 2006, J Cell Physiol, 209, 13, 10.1002/jcp.20689 · DOI · Paper page
- Sherr CJ, 1994, Cell, 79, 551, 10.1016/0092-8674(94)90540-1 · DOI · Paper page
- el-Deiry WS, 1994, Cancer Res, 54, 1169
- el-Deiry WS, 1993, Cell, 75, 817, 10.1016/0092-8674(93)90500-P · DOI · Paper page
- Waldman T, 1995, Cancer Res, 55, 5187
- Rohaly G, 2005, Cell, 122, 21, 10.1016/j.cell.2005.04.032 · DOI
- St Clair S, 2004, Mol Cell, 16, 725, 10.1016/j.molcel.2004.11.002 · DOI · Paper page
- Hermeking H, 1997, Mol Cell, 1, 3, 10.1016/S1097-2765(00)80002-7 · DOI · Paper page
- Ando T, 2001, J Biol Chem, 276, 42971, 10.1074/jbc.M106460200 · DOI · Paper page
- Zhan Q, 1999, Oncogene, 18, 2892, 10.1038/sj.onc.1202667 · DOI · Paper page
- Jin S, 2000, J Biol Chem, 275, 16602, 10.1074/jbc.M000284200 · DOI · Paper page
- Nezi L, 2009, Curr Opin Cell Biol, 21, 785, 10.1016/j.ceb.2009.09.007 · DOI · Paper page
- Cross SM, 1995, Science, 267, 1353, 10.1126/science.7871434 · DOI · Paper page
- Di Leonardo A, 1997, Cancer Res, 57, 1013
- Fukasawa K, 1996, Science, 271, 1744, 10.1126/science.271.5256.1744 · DOI · Paper page
- 10.1128/MCB.18.2.1055 · DOI · Paper page
- Smith ML, 1994, Science, 266, 1376, 10.1126/science.7973727 · DOI · Paper page
- Smith ML, 1996, Oncogene, 13, 2255
- Janus F, 1999, Cell Mol Life Sci, 55, 12, 10.1007/s000180050266 · DOI
- Gottlieb E, 2010, Cold Spring Harb Perspect Biol, 2, a001040, 10.1101/cshperspect.a001040 · DOI · Paper page
- Ma W, 2007, J Bioenerg Biomembr, 39, 243, 10.1007/s10863-007-9083-0 · DOI
- Kulawiec M, 2009, J Carcinog, 8, 8, 10.4103/1477-3163.50893 · DOI
- Lebedeva MA, 2009, Biochim Biophys Acta, 1787, 328, 10.1016/j.bbabio.2009.01.004 · DOI · Paper page
- Okamura S, 1999, Oncol Res, 11, 281
- Schwartzenberg-Bar-Yoseph F, 2004, Cancer Res, 64, 2627, 10.1158/0008-5472.CAN-03-0846 · DOI · Paper page
- Kawauchi K, 2008, Nat Cell Biol, 10, 611, 10.1038/ncb1724 · DOI · Paper page
- Bensaad K, 2007, Trends Cell Biol, 17, 286, 10.1016/j.tcb.2007.04.004 · DOI · Paper page
- Li H, 2009, J Biol Chem, 284, 1748, 10.1074/jbc.M807821200 · DOI
- Vousden KH, 2009, Biochem Soc Trans, 37, 511, 10.1042/BST0370511 · DOI
- Muniyappa H, 2009, J Biol Chem, 284, 17069, 10.1074/jbc.M109.008557 · DOI
- Budanov AV, 2004, Science, 304, 596, 10.1126/science.1095569 · DOI · Paper page
- Cano CE, 2009, Cancer Res, 69, 219, 10.1158/0008-5472.CAN-08-2320 · DOI
- Hayflick L, 1965, Exp Cell Res, 37, 614, 10.1016/0014-4827(65)90211-9 · DOI · Paper page
- Zilfou JT, 2009, Cold Spring Harb Perspect Biol, 1, a001883, 10.1101/cshperspect.a001883 · DOI · Paper page
- Gorgoulis VG, 2003, EMBO J, 22, 1567, 10.1093/emboj/cdg157 · DOI
- Dumble M, 2007, Blood, 109, 1736, 10.1182/blood-2006-03-010413 · DOI · Paper page
- Junttila MR, 2010, Nature, 468, 567, 10.1038/nature09526 · DOI · Paper page
- Feldser DM, 2010, Nature, 468, 572, 10.1038/nature09535 · DOI · Paper page
- 10.1093/carcin/23.12.2011 · DOI · Paper page
- 10.1002/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V · doi:10.1002/(sici)1097-0215(19960917)67:6<808::aid-ijc9>3.0.co;2-v
- Gomez-Manzano C, 1996, Cancer Res, 56, 694
- Gomez-Manzano C, 1997, J Natl Cancer Inst, 89, 1036, 10.1093/jnci/89.14.1036 · DOI
- 10.1097/00006123-199911000-00016 · DOI
- Li H, 1999, Clin Cancer Res, 5, 637
- Lang FF, 2003, J Clin Oncol, 21, 2508, 10.1200/JCO.2003.11.138 · DOI · Paper page
- 10.1158/1078-0432.CCR-09-1044 · DOI
- Zeimet AG, 2003, Lancet Oncol, 4, 415, 10.1016/S1470-2045(03)01139-2 · DOI · Paper page
- Nemunaitis J, 2000, Cancer Res, 60, 6359
- Shi J, 2009, Curr Opin Mol Ther, 11, 547
- 10.1007/s00432-009-0701-6 · DOI
- Tian G, 2009, Anticancer Drugs, 20, 389, 10.1097/CAD.0b013e32832a2df9 · DOI
- 10.1158/1535-7163.MCT-07-0125 · DOI
- 10.3892/or_00001018 · DOI
- Pan JJ, 2009, J Clin Oncol, 27, 799, 10.1200/JCO.2008.18.9670 · DOI
- Li Y, 2009, Clin Cancer Res, 15, 6724, 10.1158/1078-0432.CCR-09-1296 · DOI
- Keedy V, 2008, J Clin Oncol, 26, 4166, 10.1200/JCO.2007.15.6927 · DOI
- Ulasov IV, 2007, Hum Gene Ther, 18, 118, 10.1089/hum.2006.146 · DOI
- Bischoff JR, 1996, Science, 274, 373, 10.1126/science.274.5286.373 · DOI · Paper page
- Khuri FR, 2000, Nat Med, 6, 879, 10.1038/78638 · DOI · Paper page
- O'Shea CC, 2004, Cancer Cell, 6, 611, 10.1016/j.ccr.2004.11.012 · DOI · Paper page
- Chiocca EA, 2004, Mol Ther, 10, 958, 10.1016/j.ymthe.2004.07.021 · DOI · Paper page
- 10.2174/156800907780058862 · DOI
- Tyler MA, 2009, Gene Ther, 16, 262, 10.1038/gt.2008.165 · DOI
- 10.1634/stemcells.2007-0758 · DOI · Paper page
- Sherr CJ, 2006, Nat Rev Cancer, 6, 663, 10.1038/nrc1954 · DOI · Paper page
- 10.4161/cc.3.4.801 · DOI · Paper page
- Kojima K, 2005, Blood, 106, 3150, 10.1182/blood-2005-02-0553 · DOI · Paper page
- Secchiero P, 2009, Blood, 113, 4300, 10.1182/blood-2008-11-187708 · DOI
- Carter BZ, 2010, Blood, 115, 306, 10.1182/blood-2009-03-212563 · DOI
- Galatin PS, 2004, J Med Chem, 47, 4163, 10.1021/jm034182u · DOI
- Lu Y, 2006, J Med Chem, 49, 3759, 10.1021/jm060023+ · DOI
- Yin H, 2005, Angew Chem Int Ed Engl, 44, 2704, 10.1002/anie.200462316 · DOI · Paper page
- 10.1158/1535-7163.MCT-05-0199 · DOI · Paper page
- Essmann F, 2011, Br J Pharmacol
- Hardcastle IR, 2011, J Med Chem, 54, 1233, 10.1021/jm1011929 · DOI
- 10.1021/jm0601194 · DOI
- 10.4161/cc.1.6.259 · DOI
- Sur S, 2009, Proc Natl Acad Sci USA, 106, 3964, 10.1073/pnas.0813333106 · DOI · Paper page
- 1998, Crit Rev Immunol, 18, 29, 10.1615/CritRevImmunol.v18.i1-2.40 · DOI
- 10.1158/1078-0432.CCR-08-2227 · DOI · Paper page
- 10.1038/onc.2008.249 · DOI
- Bykov VJ, 2005, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Wiman KG, 2010, Oncogene, 29, 4245, 10.1038/onc.2010.188 · DOI · Paper page
- Boeckler FM, 2008, Proc Natl Acad Sci USA, 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
- 10.1101/sqb.2005.70.049 · DOI
- Demma M, 2010, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469 · DOI
- Kravchenko JE, 2008, Proc Natl Acad Sci USA, 105, 6302, 10.1073/pnas.0802091105 · DOI · Paper page
- North S, 2002, Mol Carcinog, 33, 181, 10.1002/mc.10038 · DOI
- Weinmann L, 2008, Cell Death Differ, 15, 718, 10.1038/sj.cdd.4402301 · DOI
- Belyi VA, 2010, Cold Spring Harb Perspect Biol, 2, a001198, 10.1101/cshperspect.a001198 · DOI · Paper page
- 10.1038/onc.2010.266 · DOI
- Saddler C, 2008, Blood, 111, 1584, 10.1182/blood-2007-09-112698 · DOI
- Calabro V, 2004, Mol Cell Biol, 24, 8529, 10.1128/MCB.24.19.8529-8540.2004 · DOI
- 10.1074/jbc.C600147200 · DOI · Paper page
- Wang H, 2011, Mol Cancer Ther, 10, 69, 10.1158/1535-7163.MCT-10-0581 · DOI · Paper page
- Issaeva N, 2004, Nat Med, 10, 1321, 10.1038/nm1146 · DOI · Paper page
- Smith MA, 2011, Pediatr Blood Cancer
- Bernal F, 2007, J Am Chem Soc, 129, 2456, 10.1021/ja0693587 · DOI · Paper page
Cited by
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
The lncRNA Neat1 promotes activation of inflammasomes in macrophages
Zhang, P., Cao, L., Zhou, R., Yang, X., & Wu, M. (2019) · Nature Communications · doi:10.1038/s41467-019-09482-6 · Cited by 499
Programmed cell death in aging
Tower, J. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.04.002 · Cited by 426
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
Metadata
- Authors
- Stegh, A. H.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 16
- Issue
- 1
- Pages
- 67-83
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1980250100
- Cited by
- 194
- References
- 56
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils. https://app.cochat.ai/papers/10.1517/14728222.2011.643299
- The paper
- Stegh, A. H. (2012). Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2011.643299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.